Supply Issues Update for Primary and Secondary Care: May 2021

Total Page:16

File Type:pdf, Size:1020Kb

Supply Issues Update for Primary and Secondary Care: May 2021 COMMERCIAL-SENSITIVE Supply Issues Update for Primary and Secondary Care: May 2021 This report has been produced by the Department of Health and Social Care (DHSC) Medicine Supply Team. We aim to produce this report monthly to provide an update on current primary and secondary care medicine supply issues that we are working on. This information is confidential to the NHS; please do not upload to websites in the public domain. Please do share with relevant colleagues and networks. Where it has been stated ‘a Serious Shortage Protocol (SSP) has been issued’, this will be found here. Tenecteplase (Metalyse) 10,000 units Contents powder and solvent for solution for injection New Issues ............................................................. 3 .......................................................................6 Injectables ......................................................... 3 Tetracosactide 1mg depot injection ..............6 Calcitonin (salmon) 50units/1ml solution for Urokinase (Syner-KINASE) 25,000IU injection injection ampoules ........................................ 3 .......................................................................6 Diamorphine 5mg and 10mg injection .......... 3 Verteporfin (Visudyne) 15mg powder for Orals ................................................................... 3 solution for infusion .......................................6 Irbesartan 300 mg/hydrochlorothiazide 12.5 Orals ...................................................................6 mg (CoAprovel) tablets .................................. 3 Cloral betaine 707mg tablets .........................7 Naftidrofuryl 100mg capsules ....................... 4 Chloral hydrate 143.3mg/5ml oral solution ..7 Others ................................................................ 4 Colestipol (Colestid) orange and plain 5g Fluticasone (Flixotide) 100microgram granules sachets ............................................7 Accuhaler ....................................................... 4 Colestyramine (Questran) Powder for Oral Gemeprost (Cervagem) 1mg pessary ............ 4 Suspension .....................................................7 Ongoing Issues ....................................................... 4 Contraceptive products (oral) ........................7 Injectables ......................................................... 4 Docusate sodium 100mg capsules .................8 Adrenaline Auto-Injectors (AAIs) ................... 4 Donepezil 10mg orodispersible tablets .........8 Bleomycin 15,000I.U. injection ...................... 5 Fentanyl (Abstral) 800microgram sublingual tablets ............................................................8 Diazepam (Diazemuls) 10mg/2ml emulsion for injection ................................................... 5 Fluoxetine 10mg tablets ................................8 Human normal Immunoglobulin (IVIg 10%) .. 5 Fluoxetine 30mg capsules ..............................8 Lorazepam 4mg/ml solution for injection ..... 5 Fluoxetine 40mg capsules ..............................9 Mitomycin 2mg and 10mg powder for Haloperidol 5mg/5ml oral solution sugar free solution for injection/infusion ....................... 5 .......................................................................9 Phenobarbital 30mg/ml solution for injection Histamine (H2) antagonists............................9 ....................................................................... 6 Hormone Replacement Therapy products Ranitidine 50mg/2ml injection ...................... 6 (HRT) ........................................................... 10 Somatropin 200microgram MiniQuick Irbesartan 150 mg/hydrochlorothiazide 12.5 (Genotropin) device ....................................... 6 mg (CoAprovel) tablets ............................... 10 1 COMMERCIAL-SENSITIVE Isosorbide mononitrate (Isotard) 50mg Ciprofloxacin (Ciproxin) 100mg/50ml solution modified release tablets .............................. 10 for infusion (Bayer) ..................................... 14 Isosorbide Mononitrate (Imdur) 60mg Coal tar (Psoriderm) emulsion (Dermal) ..... 14 modified release tablets .............................. 11 Desmopressin (DDAVP) 0.01% w/v intranasal Itraconazole 10mg/ml oral suspension ....... 11 solution (Ferring) ........................................ 14 Mianserin 10mg tablets ............................... 11 Efavirenz (Sustiva) 50mg, 100mg & 200mg Moclobemide 150mg and 300mg tablets.... 11 capsules and 600mg tablets (Bristol Myers Squibb) ........................................................ 14 Phenelzine sulphate (Nardil) 15mg tablets . 11 Estradiol hemihydrate (Elleste Solo MX) Phillips' Milk of Magnesia 415mg/5ml 40microgram and 80microgram patches (magnesium hydroxide) oral suspension ..... 11 (Viatris) ........................................................ 15 Pioglitazone 15mg/metformin 850mg Fosamprenavir (Telzir) 50mg/ml oral (Competact) tablets ..................................... 11 suspension (ViiV Healthcare) ...................... 15 Prazosin (Hypovase) 1mg tablets ................ 12 Gabapentin 400mg capsules (Tillomed) ..... 15 Promethazine 25mg tablets ........................ 12 Lacidipine 2mg tablets (Teva) ..................... 15 Ranitidine oral preparations ........................ 12 Losartan 100mg / Hydrochlorothiazide Rifampicin 300mg/isoniazid 150mg (Rifinah) 12.5mg tablets (Teva) ................................. 15 tablets .......................................................... 12 Methadone (Physeptone) 5mg tablets Tapentadol (Palexia) 20mg/ml oral solution (Martindale) ................................................ 15 ..................................................................... 12 Mirtazapine 45mg tablets (Teva) ................ 15 Trifluoperazine 1mg/5ml syrup ................... 12 Neomycin 500mg tablets (Advanz Pharma) 15 Tuberculosis medications ............................ 12 Pregabalin 25mg, 50mg and 225mg capsules Voriconazole 40mg/ml powder for oral (Tillomed) .................................................... 16 suspension ................................................... 12 Repaglinide (Prandin) 500microgram, 1mg & Other ................................................................ 13 2mg tablets (Novo Nordisk) ........................ 16 Desmopressin (Desmospray) Sodium bicarbonate 500mg capsules (Teva) 10micrograms/actuation nasal spray .......... 13 .................................................................... 16 Desmopressin (Octim) Tramadol (Zydol) 50mg capsules x 30 pack 150microgram/actuation nasal spray ......... 13 (Grunenthal) ............................................... 16 Fentanyl (Instanyl) 100 microgram and 200 Tramadol 50mg capsules (Teva) ................. 16 microgram nasal sprays ............................... 13 Tramadol 37.5mg / Paracetamol 325mg Fludroxycortide 0.0125% cream .................. 13 tablets (Teva) .............................................. 16 Metronidazole (Acea) 0.75% gel .................. 13 Resolved .............................................................. 17 Vaccines ........................................................... 13 Acetazolamide SR (Diamox SR) 250mg capsules (23/4/21) ...................................... 17 Pneumovax 23 pre-filled syringes ............... 14 Atracurium besilate solution for injection Discontinuations .................................................. 14 vials and ampoules (all strengths) (4/21) ... 17 Alfuzosin (Xatral) 2.5mg tablets (Sanofi) ..... 14 Balneum Bath Additive (4/4/21) ................. 17 Amisulpride (Solian) 100mg/ml oral solution Balneum Plus bath oil (26/4/21) ................. 17 (Sanofi) ......................................................... 14 2 COMMERCIAL-SENSITIVE Cimetidine 200mg/5ml oral solution (sugar Granisetron (Sancuso) 3.1mg/24 hours free) (9/4/21) ............................................... 17 transdermal patches (20/4/21) .................. 17 Crisantaspase (Erwinase) injection (6/4/21)17 Mianserin 30mg tablets (16/4/21).............. 17 Diltiazem (Zemtard) 240mg Capsules (5/5/21) Repaglinide 1mg and 2mg tablets (5/5/21) 17 ..................................................................... 17 Sodium cromoglycate (Intal) 5mg inhaler Dorzolamide (Eydelto) 20mg/mL preservative (5/5/21) ....................................................... 17 free eye drops (16/4/21) ............................. 17 Voriconazole 200mg powder for solution for Enalapril 5mg tablet (15/4/21) .................... 17 infusion (21/4/21) ....................................... 17 Ethinylestradiol 30microgram/drospirenone Zonisamide 25mg capsules (14/4/21) ........ 17 3mg (Yasmin) tablets (10/4/21)................... 17 Zonisamide 50mg capsules (14/4/21) ........ 17 Ethinylestradiol 35 microgram/cyproterone Appendix ............................................................. 18 2mg tablets (Dianette) tablets (22/3/21) .... 17 Table 2: HRT availability and anticipated Ferrous fumarate 322mg/Folic Acid 0.35mg resolution dates .......................................... 18 (Pregaday) tablets (26/4/21) ....................... 17 Information provided: w/c 3 May 2021 New Issues Injectables Calcitonin (salmon) 50units/1ml solution for injection ampoules • Essential Pharma, sole supplier is out of stock until March 2022. • Calcitonin (salmon) 100units/1ml solution for injection ampoules remain available and can support the uplift in demand. Diamorphine 5mg and 10mg injection • There have been intermittent supplies of diamorphine 5mg and 10mg injections
Recommended publications
  • Naftidrofuryl-Induced Acute Hepatic Necrosis
    Postgraduate Medical Journal (1986) 62, 309-3 10 Postgrad Med J: first published as 10.1136/pgmj.62.726.309 on 1 April 1986. Downloaded from Naftidrofuryl-induced acute hepatic necrosis J.S. de Caestecker and R.C. Heading Department ofMedicine, Royal Infirmary, Edinburgh EH3 9YW, UK. Summary: Acute hepatic necrosis is described in a 60 year old woman treated with naftidrofuryl for 5 months. Introduction Naftidrofuryl oxalate (Praxilene, Lipha) is a were demonstrated within the gallbladder. Liver vasodilator advocated for cerebral and peripheral biopsy showed extensive centrilobular necrosis with vascular disease. There have been no previous reports porto-central bridging (Figure 1). Serological tests for of hepatic damage due to this drug. We now wish to hepatitis A, hepatitis B, toxoplasma, cytomegalovirus, report a case in which severe hepatitis was related to its herpes simplex, coxiella, mycoplasma, brucella and use. leptospira were negative. Antibody to Epstein-Barr virus (IgG type) indicated past infection. Antimito- chondrial and anti-smooth muscle antibodies were Case history absent. All medication was discontinued on admission and A 60 year old woman with a history ofischaemic heart the patient made a good recovery. Four months later, disease presented with 5 months of nausea and one her bilirubin was 23 gmol/l, ALT 57 units/l, alkaline copyright. month of anorexia. She had noticed increasing jaun- phosphatase 178 units/l, gamma glutamyl transferase dice, dark urine and pale stools for 10 days. She had 112 units/l and albumin 37 g/l, and one year later her not been in contact with viral hepatitis and had not liver function tests were normal.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Application of Prioritization Approaches to Optimize Environmental Monitoring and Testing of Pharmaceuticals
    This is a repository copy of Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/130449/ Article: Burns, Emily E orcid.org/0000-0003-4236-6409, Carter, Laura J, Snape, Jason R. et al. (2 more authors) (2018) Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals. Journal of Toxicology and Environmental Health, Part B: Critical Reviews. pp. 115-141. ISSN 1521-6950 https://doi.org/10.1080/10937404.2018.1465873 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals Emily E. Burns,† Laura J. Cater,‡ Jason Snape,§ Jane Thomas-Oates,† Alistair B.A. Boxall*‡ †Chemistry Department, University of York, Heslington, YO10 5DD, United Kingdom ‡Environment Department, University of York, Heslington, YO10 5DD, United Kingdom §AstraZeneca UK, Global Safety, Health and Environment, Macclesfield, SK10 4TG, United Kingdom *Address correspondence to [email protected] Emily E.
    [Show full text]
  • From Tinnitus to Acute Hepatitis: Drug-Induced Injury Caused by Use
    Clinics and Research in Hepatology and Gastroenterology (2019) 43, e93—e94 Available online at ScienceDirect www.sciencedirect.com LETTER TO THE EDITOR Liver enzymes were normal one year before when a blood From tinnitus to acute hepatitis: test was performed by the Occupational Medicine service. Drug-induced injury caused by use of Laboratory examination revealed cytolysis with a pre- naftidrofuryl for one year dominantly high alanine aminotransferase level associated with icteric cholestasis (Table 1). Blood tests for the most common causes, including hep- KEYWORDS atitis A, B, C and E, Epstein Barr virus, cytomegalovirus, Naftidrofuryl; autoimmune hepatitis and Wilson’s disease were negative. Acute hepatitis; An abdominal ultrasound was normal. Cholangio magnetic Drug-induced liver injury resonance imaging showed no cholelithiasis. A liver biopsy showed lesions consistent with drug- induced involvement, with many eosinophilic cells. The Naftidrofuryl is a vasodilator marketed in Europe for the other abnormalities included an inflammatory infiltrate in treatment of intermittent claudication in chronic arteriopa- the portal spaces attacking the border blade and lesions of thy, but is also used for the treatment of tinnitus. cholangitis (Fig. 1). We report a case of acute cytolytic hepatitis induced by One month after stopping naftidrofuryl, cytolysis naftidrofuryl. regressed and asthenia decreased (Table 1). Due to the A 61-year-old woman was seen in consultation for strong likelihood of drug toxicity we filed a statement with elevated liver enzymes in a blood sample performed pharmacovigilance. for asthenia. Her medical history included hepatitis A, The diagnosis of drug-induced liver injury relies on clin- endometriosis and appendectomy. ical and chronological criteria [1].
    [Show full text]
  • Enhanced Reference List of Cochrane Review Protocols
    Enhanced Reference List of Cochrane Review Protocols Selected by the Cochrane Neurological Network Published in the Cochrane Library (CL) through Issue 3, 2006 This database of COCHRANE REVIEW PROTOCOLS contains titles - in alphabetical order - of protocols – of neurological interest – published in the Cochrane Library through Issue 3, 2006. They were selected and compiled by the Cochrane Neurological Network. The standard path for registering a systematic review is the registration of the title, the submission of the protocol and, finally, the completed review. These protocols are divided by disease category according to the Index of Diseases created and maintained by the Cochrane Neurological Network. See the Index of Diseases - in alphabetical order - with the corresponding number of protocols that can be found in this list. (Last update: 26 September 2006) Index of Diseases ACQUIRED METABOLIC DISORDERS ( 1 ) MIGRAINE AND HEADACHE ( 13 ) ALCOHOL AND ALCOHOLISM ( 2 ) MOTOR NEURON DISEASES ( 7 ) BACK ( 11 ) MOVEMENT DISORDERS ( 14 ) BRAIN AND SPINAL CORD TUMORS ( 5 ) NEUROLOGICAL SERVICES ( 1 ) BRAIN AND SPINAL INJURIES ( 16 ) NEUROMUSCULAR DISORDERS ( 9 ) CEREBROVASCULAR DISEASE - ACUTE TREATMENT ( 14 ) NEUROSURGERY ( 1 ) CEREBROVASCULAR DISEASE - PREVENTION ( 20 ) NUTRITIONAL DEFICIENCY DISORDERS ( 0 ) CEREBROVASCULAR DISEASE-Rehabilitation/Post Acute ( 12 ) PAIN ( 11 ) CSN AND SPINAL INFECTIONS ( 5 ) PERIPHERAL AND CRANIAL NERVES NEUROPATHIES ( 21 ) DEMENTIA ( 24 ) RARE AND HEREDITARY DISEASES ( 2 ) DEMYELINATING DISEASES ( 13 ) SLEEP DISORDERS ( 8 ) EPILEPSY ( 10 ) SUBARACHNOID HAEMORRHAGE ( 0 ) INTENSIVE CARE AND PALLIATIVE CARE ( 3 ) SYMPTOMATIC TREATMENT ( 36 ) INTOXICATIONS AND POISONINGS ( 0 ) OTHERS ( 8 ) ACQUIRED METABOLIC DISORDERS Magnesium sulfate for term infants following perinatal asphyxia Kent A, Kecskes Z; Neonatal Group In: The Cochrane Library, Issue 2, 2005.
    [Show full text]
  • Pilot Experiments on the Actions of Drugs Injectedinto
    Br. J. Pharmac. (1986), 87, 495-500 Pilot experiments on the actions ofdrugs injected into the human corpus cavernosum penis G.S. Brindley Department ofPhysiology, Institute of Psychiatry De Crespigny Park, London SE5 8AF 1 Seven drugs that are known to relax smooth muscle (phenoxybenzamine, phentolamine, thymoxamine, imipramine, verapamil, papaverine, naftidrofuryl) caused erection when injected intracavernosally. 2 Salbutamol, hydralazine, lignocaine and bupivacaine caused tumidity but not erection. 3 Metaraminol and guanethidine caused shrinkage followed by tumidity. 4 Neostigmine, atropine, propranolol and idazoxan had no effect in the doses tried. 5 It is argued that the seven drugs that cause erection do so by relaxing vascular and trabecular smooth muscle within the cavernosal space, and that the two that cause shrinkage ofthe penis do so by constricting vascular and trabecular smooth muscle within the cavernosal space. 6 It is argued that muscarinic and P-adrenergic transmission play no important part in erectile mechanisms within the corpora cavernosa. 7 Papaverine, phenoxybenzamine and metaraminol, given intracavernosally, are already used therapeutically. Uses are suggested for thymoxamine, phentolamine, verapamil and guanethidine. Introduction Papaverine (Virag, 1982) and phenoxybenzamine and the left corpus cavernosum was squeezed in the same phentolamine (Brindley, 1983a; 1983b) cause erection way; then the penis was firmly pinched transversely at when given by intracavernosal injection. least six different places along it length in succession. Metaraminol, given by the same route, shrinks the These three actions were then repeated. penis (Brindley, 1984a). These drugs are now in The drugs were injected in a volume of 2 ml or less, therapeutic use (Virag, 1982; Virag et al., 1984; except for phenoxybenzamine, hydralazine and naf- Brindley, 1983b; 1984a,b; 1986; Zorgniotti & Lefleur, tidrofuryl, which were diluted with 10 ml of 0.9% 1985).
    [Show full text]
  • Ergot Derivatives Art. 31
    27 September 2013 EMA/750632/2013 Assessment report Ergot derivatives containing medicinal products International Non-proprietary Name: nicergoline Procedure number: EMEA/H/A-31/1325 Referral under Article 31 of Directive 2001/83/EC Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical efficacy .................................................................................................... 4 2.2.1. Results ............................................................................................................. 4 2.2.2. Discussion ........................................................................................................ 9 2.3. Clinical safety ...................................................................................................
    [Show full text]
  • Interactions with HBV Treatment
    www.hep-druginteractions.org Interactions with HBV Treatment Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF. ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoflurane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ketamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrous oxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erythromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ Tizanidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gentamicin ◆ ◆ ◆ ◆ ◆ ◆ Analgesics Imipenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aceclofenac ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoniazid ◆ ◆ ◆ ◆ ◆ ◆ Alfentanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aspirin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Linezolid ◆ ◆ ◆ ◆ ◆ ◆ Buprenorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Celecoxib ◆ ◆ ◆ ◆ ◆ ◆ ◆ Meropenem ◆ ◆ ◆ ◆ ◆ ◆ Codeine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dexketoprofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Metronidazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dextropropoxyphene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Use of Phentolamine for the Manufacture of a Medicament for the Treatment of Erectile Dysfunction
    Patentamt Europaisches |||| ||| 1 1|| ||| ||| || || || || || || || || || (19) J European Patent Office Office europeen des brevets (11) EP 0 962 225 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication:ation: (51 ) |nt. CI.6: A61 K 31 /41 5 08.12.1999 Bulletin 1999/49 (21) Application number: 99114470.0 (22) Date of filing: 26.04.1996 (84) Designated Contracting States: (72) Inventor: Lowrey, Fred AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC Lincoln, NE 6851 2 (US) NL PT SE (74) Representative: (30) Priority: 28.04.1995 US 431145 Walton, Sean Malcolm et al MEWBURN ELLIS, (62) Document number(s) of the earlier application(s) in York House, accordance with Art. 76 EPC: 23 Kingsway 9691 31 74.7 / 0 767 660 London WC2B 6HP (GB) (71) Applicant: ZONAGEN, INC. Remarks: The Woodlands, TX 77380 (US) This application was filed on 23 - 07 - 1 999 as a divisional application to the application mentioned under INID code 62. (54) Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction (57) The invention is directed to improved methods for modulating the human sexual response by adminis- tering an oral administered formulation of a vasodilator agent to the blood circulation thereby modulating the sexual response on demand. CM < CM CM CM CO <7> O Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 962 225 A2 Description FIELD OF THE INVENTION 5 [0001] The application is directed to improved formulations for the administration of vasodilator agents to the blood circulation of a human in order to modulate the human sexual response on demand.
    [Show full text]
  • Neemmc Guidelines for Tablet Crushing and Administration Via Enteral Feeding Tubes
    NEEMMC GUIDELINES FOR TABLET CRUSHING AND ADMINISTRATION VIA ENTERAL FEEDING TUBES KEY TO DRUG ADMINISTRATION GUIDELINES Please follow the guidelines in order, as shown in the chart (i.e. number 1 is the first choice of which form to administer the drug in). A Tablet will disperse in 1-2 minutes. B Tablet will disperse in greater than 2 minutes. C Liquid preparation available. D Dilute reconstituted injection with 30-60ml of water before administering. E Oral solution/suspension can be prepared by local pharmacy or Non Sterile Preparative Services (PSU at Colchester General Hospital). Note: It is an unlicensed use to crush tablets, open capsules and make extemporaneous suspensions. However, using tablets within these guidelines is covered by the Trust for legal/vicarious liability. For more information on the administration via different tubes, please contact Medicines Information on ext. 2161. Drug Key code Information ACETAZOLAMIDE 1. A* * Diamox SR capsules can be opened and 2. D the contents flushed down the enteral tube 3. E ACICLOVIR 1. C * Dispersible tablets available 2. A* ALFACALCIDOL C* * Drops available. Sensitive to light ALFUZOSIN A Beware of sudden hypotensive effect if giving crushed tablets. Monitor BP and ensure patient is lying down prior to administering the dose. Do not crush slow release preparations. ALLOPURINOL 1. B 2. E ALVERINE Content of capsules is very bitter, and might numb the tongue and throat. AMILORIDE 1. B 2. C* * Liquid available. AMINOPHYLLINE Convert to theophylline liquid equivalent. Do not crush SR preparations. AMIODARONE B AMITRIPTYLINE 1. C 2. B AMLODIPINE A A Tablet will disperse in 1-2 minutes.
    [Show full text]